Hydrogen Dialysis Reduces Fatigue in Kidney Disease Patients

Authors
Journal
Nature Scientific Reports
Year
DOI
10.1038/s41598-025-88827-2
Study Type
Human
Outcome
Positive
Peer Reviewed
Yes
Country
Japan
Health Condition
Chronic Kidney Disease
Body System
Renal

TL;DR

Using hydrogen-enriched dialysis solution in hemodialysis appears to reduce fatigue in patients who experience it, particularly on dialysis days, and may improve their energy metabolism.

Key Finding

Hemodialysis patients with activity-limiting fatigue experienced significant fatigue reduction after 12 months of hydrogen-enriched dialysis treatment, with changes in energy metabolism pathways suggesting this may be the mechanism of improvement.

Summary

This study followed 81 hemodialysis patients for 12 months to see if using hydrogen-enriched dialysis solution (created through water electrolysis) could reduce fatigue. Patients were grouped by fatigue severity. Those with fatigue that limited their activities showed significant improvement after 12 months of hydrogen-enriched dialysis, while those without fatigue or with fatigue that didn't limit activities saw no change. The researchers found that hydrogen-enriched dialysis appeared to affect how patients' bodies produce and use energy, particularly in pathways involving fat burning and glucose metabolism.

Practical Takeaway

This human study suggests hydrogen-enriched dialysis may help reduce fatigue in dialysis patients, particularly those whose fatigue interferes with daily activities. However, the study involved only 81 patients and focused on a specific patient population (those on hemodialysis), so results may not apply to other groups. More research is needed to confirm these findings and understand exactly how hydrogen affects energy metabolism in dialysis patients.

Abstract

Hemodialysis employing molecular hydrogen (H2)-enriched dialysis solution rendered by water electrolysis (E-HD), has been reported to alleviate dialysis-related fatigue, but its association with metabolic profiles remains unclear. Eighty-one patients undergoing standard HD were classified into 3 groups [Group A (n = 25, 30.9%): fatigue with activity reduction-subgroups A1: chronic persistent fatigue (n = 11), A2: fatigue only on dialysis days (n = 14); Group B: fatigue without activity reduction (n = 24, 29.6%); Group C (n = 32, 39.5%): no fatigue], and their changes in fatigue, body composition, and metabolic profiles were studied following 12 months of E-HD. There were no significant differences in baseline characteristics among the groups. Over the 12 months after E-HD initiation, fatigue in Group A significantly decreased, while no changes in Group-B and C. Bio-impedance analysis revealed no significant changes in A1, but significant reductions in body fat and increases in skeletal muscle mass were observed despite no significant weight change in A2. Enrichment analysis suggested significant differences in metabolic pathways such as fatty acid metabolism, citric acid cycle, and glycolysis between Groups A and C at baseline, and these differences were mitigated by E-HD. E-HD could suppress dialysis-related fatigue, through possible involvement of altered energy metabolism of patients. E-HD may represent a new paradigm for uremia treatment beyond traditional solute removal-based dialysis therapies.